Stock screenerAll disclosures →
EDGAR →
DMAC
SetupConviction 63LongHealthcareScan · Fri, Oct 9, 2026Bull flagchannel
DiaMedica Therapeutics Inc. (DMAC) closed at $8.33 (+4.00%) on Oct 9, 2026. It is in the "Setting up" lane with a bull flag pattern. Price is above its 50-day and above its 200-day moving average. RSI(14) 66, RS Rating 85, -11.3% from its 52-week high, +5.0% year to date. Sector: Healthcare · PHARMACEUTICAL PREPARATIONS.
DMAC$8.33+4.00%
ResistanceSupportVol 14Vol MA14 243.05K
Jul 14Jul 30Aug 18Sep 3Sep 23Oct 9
Trade plan
LongReward : Risk1.52Entry
Entry
8.63
Risk
Stop
7.99
-7.4% to stop
Reward
Target 1
9.60
+11.2% to target
Stretch
Target 2
10.57
+22.5% to T2
Risk : reward balance
Risk to stopReward to target
Levels are derived from the pattern's structure (resistance, support and ATR) — a mechanical plan, not financial advice. Size positions to your own risk tolerance.
Price8.33
Change+4.00%
Gap+0.56%
Rel volume0.66×
Avg volume231.4K
Avg $ vol1.8M
SMA 207.70
SMA 507.05
SMA 2007.09
Price vs 50+18.15%
Price vs 200+17.46%
MA stackmixed
50/200 cross—
Supertrendup · 7.13
RSI (14)66
MACD hist0.01
MACD cross—
Stoch %K / %D77 / 70
ADX (14)39
+DI / −DI26 / 13
RSI divergence—
MACD divergence—
ATR %5.09%
ADR %5.44%
52w high9.39
52w low5.33
From 52w high-11.29%
Above 52w low+56.29%
New 52w highNo
SqueezeOff
Bollinger width33.90%
%B0.74
Donchian pos86.78%
Donchian high8.63
Donchian low6.36
AVWAP (52w high)7.39
vs AVWAP high+12.79%
AVWAP (52w low)7.06
vs AVWAP low+18.04%
OBV trendUp
Chaikin MF (20)0.18
Today vs 20d0.66×
Avg vol (14d)243.04K
Avg vol (20d)231.4K
Avg $ vol (20d)1.8M
Market cap449.2M
RS Rating85 / 99
RS 3m (vs SPY)+7.30%
RS 6m (vs SPY)+24.49%
RS line new highNo
Trend template5/8
Technical rank93.5
1 week+1.22%
1 month+28.75%
3 months+11.21%
6 months+39.07%
1 year+19.68%
YTD+5.04%
P/E-13.71
P/B11.72
P/S898.40
P/FCF-15.44
EPS-0.6500
Div yield—
ROE-85.47%
ROA-72.81%
Debt/Eq—
Current6.72
EV/EBITDA—
Gross margin—
Net margin—
Rev growth0.00%
EPS growth-34.05%
Price target12.00
Target upside44.06%
Analyst ratingBuy
Institutional26.10%
Ent. value444.07M
Revenue500K
Net income-10.14M
Gross profit—
Free cash flow-29.1M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out53.88M
Employees35
ListedThu, Nov 29, 2007
Free float23.38M
Float %44.9%
Short interest5.39M
Days to cover47.2d
Short volume72.3%
Squeeze score85 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.19 vs −$0.19
Last surprise0.0% beat
Setup gradeB
Conviction63 / 100
Pattern quality90%
Tech rank93.5 / 100
Group rank14 / 100
Status laneSetting up
Setup directionLong
Pattern familyChannel
Resistance8.63
Support7.66
Days since event—
Candle confirm—
Financials as of Tue, Jun 30, 2026 · quarterly.
Signal lifecycle
How this symbol has moved through the lanes across 60 scans — each scan is re-classified from that day's price, so gaps are days it dropped off the board entirely.
- Setting upAug 41 scan
- Breaking out nowAug 51 scan
- Setting upSep 16 – Oct 93 scans
Recent news
- DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR ResultsYahoo Finance · Wed, Sep 30, 2026
- DiaMedica Therapeutics to Participate in Upcoming September Investor ConferencesYahoo Finance · Wed, Sep 2, 2026
- Wall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a BetYahoo Finance · Wed, Aug 26, 2026
- DiaMedica (DMAC) Q2 2026 Earnings Call TranscriptMotley Fool · Mon, Aug 17, 2026
- All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to BuyYahoo Finance · Thu, Aug 13, 2026
- DiaMedica Therapeutics Inc (DMAC) (Q2 2026) Earnings Call Highlights: Promising Preeclampsia ...Yahoo Finance · Tue, Aug 11, 2026
- DiaMedica Therapeutics Inc. Q2 2026 Earnings Call SummaryMoby · Tue, Aug 11, 2026
- DiaMedica Therapeutics Q2 Earnings Call HighlightsMarketbeat · Tue, Aug 11, 2026
- DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business HighlightsYahoo Finance · Mon, Aug 10, 2026
- DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026Yahoo Finance · Tue, Aug 4, 2026
Congress activity
Disclosed STOCK Act trades in DMAC
No recent disclosed trades by Congress in DMAC. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in DMAC
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Pauls Dietrich John President & CEO · Voting Common Shares, no par value per share · 2026-08-10 | Grant | 60.2K | — | 2026-08-10 | 2026-08-12 |
Kuntz Richard Director · Stock Option (right to buy) · 2026-06-01 | Grant | 40.41K | $0 | 2026-06-01 | 2026-06-03 |
Parsons James T. Director · Stock Option (right to buy) · 2026-06-01 | Grant | 51.19K | $0 | 2026-06-01 | 2026-06-03 |
Semba Charles Pauling Director · Stock Option (right to buy) · 2026-06-01 | Grant | 40.41K | $0 | 2026-06-01 | 2026-06-03 |
Giuffre Randall Michael Director · Stock Option (right to buy) · 2026-06-01 | Grant | 40.41K | $0 | 2026-06-01 | 2026-06-03 |
Kellen Scott CFO & Secretary · Stock Option (right to buy) · 2026-06-01 | Grant | 162K | $0 | 2026-06-01 | 2026-06-03 |
O'Connor Daniel J. Director · Stock Option (right to buy) · 2026-06-01 | Grant | 40.41K | $0 | 2026-06-01 | 2026-06-03 |
Krop Julie Chief Medical Officer · Stock Option (right to buy) · 2026-06-01 | Grant | 67.5K | $0 | 2026-06-01 | 2026-06-03 |
Lewis Tanya Director · Stock Option (right to buy) · 2026-06-01 | Grant | 40.41K | $0 | 2026-06-01 | 2026-06-03 |
Pauls Dietrich John President & CEO · Stock Option (right to buy) · 2026-06-01 | Grant | 380K | $0 | 2026-06-01 | 2026-06-03 |
SEC filings
EDGAR filings in DMAC · 2 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.